ZURICH (Reuters) - Shares in Swiss group Actelion climbed more than five percent to their highest since late 2007 on Monday on optimism it has a viable product to secure sales and profit after U.S. approval for a new heart and lung drug with a favorable label. The Food and Drug Administration approved the Swiss biotech company's pulmonary arterial hypertension (PAH) drug Opsumit late on Friday and, notably, did not impose a black box warning requiring ongoing mandatory liver testing. ...
via Health News Headlines - Yahoo! News http://news.yahoo.com/actelion-hits-six-high-favorable-fda-approval-drug-085522857--finance.html
No comments:
Post a Comment